Video

Dr. Terashima on Bursectomy for Subserosal and Serosal Gastric Cancer

Masanori Terashima, MD, PhD, FACS, chairman of the Japanese Clinical Oncology Group, discusses bursectomy for patients with subserosal and serosal gastric cancer.

Masanori Terashima, MD, PhD, FACS, chairman of the Japanese Clinical Oncology Group, discusses bursectomy for patients with subserosal and serosal gastric cancer.

In Japan, since the 1950s, bursectomy was standard treatment for patients with advanced gastric cancer. However, due to negative reports, omentectomy became the new standard until a small, randomized phase II study was performed comparing bursectomy with non-bursectomy.

According to the trial, bursectomy seems to improve survival outcomes. However, due to the small sample size, researchers could not detect a significant enough difference between the 2 arms.

Related Videos
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Elias Jabbour, MD